ArticleTherapeutic advances in medical oncology2025

Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Caicong You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.